<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496402</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2017-02</org_study_id>
    <nct_id>NCT03496402</nct_id>
  </id_info>
  <brief_title>Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)</brief_title>
  <acronym>MICCHADO</acronym>
  <official_title>Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methodology:

      Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To identify and characterise:

        -  meaningful molecular genetic alterations,

        -  meaningful immunological features of high risk childhood, adolescents and young adult
           cancers, at diagnosis, during patient treatment and follow-up (time dimension).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with meaningful molecular genetic alterations</measure>
    <time_frame>At the end of study (6 years)</time_frame>
    <description>Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with meaningful immunological features</measure>
    <time_frame>At the end of study (6 years)</time_frame>
    <description>Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)</measure>
    <time_frame>up to 6 years</time_frame>
    <description>Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between disease recurrence and molecular and/or immunological biomarkers</measure>
    <time_frame>up to 6 years</time_frame>
    <description>To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes.
To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes.
To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between genetic variations and immune parameters</measure>
    <time_frame>up to 6 years</time_frame>
    <description>To compare molecular and immunological findings at diagnosis and during treatment (data integration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between disease staging and immunological features</measure>
    <time_frame>up to 6 years</time_frame>
    <description>To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Ewing Sarcoma Family of Tumors</condition>
  <condition>Osteosarcoma</condition>
  <condition>Leukemia</condition>
  <condition>Central Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>High risk Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling on blood, bone marrow and cerebrospinal fluid</intervention_name>
    <description>biological sampling during treatment and follow-up</description>
    <arm_group_label>High risk Cohorts</arm_group_label>
    <arm_group_label>Low risk Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inclusion within 3 months after diagnosis

          2. Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph
             nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of
             lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine
             procedure

          3. Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary
             and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a
             routine procedure (except for leukaemia patients)

          4. Age: ≤ 25 years at diagnosis

          5. Written patient informed consent, or parents or legal representative written informed
             consent and assent of the child and the adolescent

          6. Compulsory affiliation to a social security scheme

             Additional inclusion criteria for the study:

             To avoid multiple sampling for children, adolescents and young adults with cancer,
             patients already included or to be included in a study with similar analyses and/or
             objectives might also be included in MICCHADO study and in this case, samples or data
             might be exchanged on a collaborative basis.

             Cohort 1:

               -  High risk neuroblastoma:

                  - Any type of neuroblastoma with MYCN amplification, except INSS stage 1

                  - Stage 4 neuroblastoma in children older than one year at diagnosis

               -  High risk rhabdomyosarcoma:

                    -  Foxo1 rearrangement any stage;

                    -  and / or N1 ;

                    -  and / or metastatic rhabdomyosarcoma

               -  High risk Ewing sarcoma:

                    -  Metastatic Ewing sarcoma family of tumours (ESFT)

                    -  Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml

               -  High risk osteosarcoma:

                  - Metastatic osteosarcoma

                  - Localised inoperable osteosarcoma

               -  High risk leukaemia:

                    -  Secondary acute myeloid leukaemia

                    -  Biphenotypic acute leukaemia

             Cohort 2:

             • Extra cerebral or cerebral high risk tumours including:

               -  other metastatic sarcomas,

               -  other rare high risk cancers,

               -  high risk renal tumours with surgery after an initial chemotherapy

               -  rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours

               -  high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic
                  leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute
                  lymphoblastic leukaemia:

               -  MRD ≥ 10-2 at the end of the induction ;

               -  or MRD ≥ 10-3 at Day 78

             Cohort 3:

             Children, adolescents and young adults, with low/intermediate risk cancers belonging
             to the following types:

             • Neuroblastoma:

             - Localised, without MYCN amplification

               -  Localised, INSS stage 1, with MYCN amplification

               -  Stage 4s, in infants (younger than one year at diagnosis), without MYCN
                  amplification

                  • Rhabdomyosarcoma:

               -  Localised, without Foxo1 rearrangement

                  • ESFT:

               -  All non-high risk localised ESFT • Osteosarcoma:

               -  All non-high risk localised osteosarcoma

             Exclusion Criteria:

             Main non-inclusion Criteria common to all study cohorts:

        1) Age: patients &gt; 25 years old at diagnosis 2) Absence of patient or parents or legal
        representative written informed consent 3) Patient for whom follow-up by the investigating
        centre does not appear feasible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gudrun SCHLEIERMACHER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gudrun SCHLEIERMACHER, MD</last_name>
    <phone>+33(0)144324554</phone>
    <email>gudrun.schleiermacher@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eve LAPOUBLE, PhD</last_name>
    <phone>+33(0)156245811</phone>
    <email>eve.lapouble@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu D'Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine DEVOLDERE, MD</last_name>
      <email>devoldere.catherine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle PELLIER, MD</last_name>
      <phone>(+33) 02.41.35.38.63</phone>
      <email>ispellier@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Besançon - Hôpital Jean-Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien KLEIN, MD</last_name>
      <phone>(+33) 03 81 21 81 38</phone>
      <email>s1klein@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital des enfants - Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves PEREL, MD</last_name>
      <phone>(+33) 05 57 82 04 38</phone>
      <email>yves.perel@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liana-Stéphania CARAUSU, MD</last_name>
      <phone>(+33) 02 98 22 37 70</phone>
      <email>liana.carausu@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianna DEPARIS, MD</last_name>
      <phone>(+33) 02 31 06 50 82</phone>
      <email>deparis-m@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Cancérologie et Thrapie Cellulaire Pdiatrique (CRCTCP)</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justyna KANOLD, MD</last_name>
      <phone>(+33) 04 73 75 00 09</phone>
      <email>jkanold@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital d'Enfants</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire BRIANDET, MD</last_name>
      <phone>(+33) 03 80 29 36 01</phone>
      <email>claire.briandet@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU GRENOBLE Alpes - Hôpital Couple-Enfant</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique PLANTAZ, MD</last_name>
      <phone>(+33) 04 76 76 59 11</phone>
      <email>DPlantaz@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Sophie DEFACHELLESTHOMASSIN, MD</last_name>
      <phone>(+33) 03 20 59 06</phone>
      <email>AS-Defachelles@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Mère-Enfant</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PIGUET, MD</last_name>
      <phone>(+33) 05 55 05 68 01</phone>
      <email>christophe.piguet@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadège CORRADINI, MD</last_name>
      <phone>(+33) 04 78 78 26 42</phone>
      <email>Nadege.corradini@ihope.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves BERTRAND, MD</last_name>
      <phone>(+33) 04 69 16 65 70</phone>
      <email>Yves.bertrand@ihope.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants de la Timone (AP-HM)</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole COZE, MD</last_name>
      <email>carole.coze@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure SAUMET, MD</last_name>
      <phone>(+33) 04 67 33 65 19</phone>
      <email>l-saumet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôpital Mère Enfant</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte RIGAUD, MD</last_name>
      <phone>(+33) 02 40 08 36 10</phone>
      <email>charlotte.rigaud@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>BP 3079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Simon ROHRLICH, MD</last_name>
      <phone>(+33) 04 92 03 92 68</phone>
      <email>rohrlich.ps@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud PETIT, MD</last_name>
      <phone>(+33) 01.71.73.82.57</phone>
      <email>arnaud.petit@trs.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Robert-Debré (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André BARUCHEL, MD</last_name>
      <phone>(+33) 01 40 03 53 88</phone>
      <email>andre.baruchel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>750248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun SCHLEIERMACHER, MD</last_name>
      <phone>+ 00 33 (0)1.44.32.45.51</phone>
      <email>gudrun.schleiermacher@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric MILLOT, MD</last_name>
      <phone>(+33) 05.49.44.30.78</phone>
      <email>f.millot@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Américain</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire PLUCHART, MD</last_name>
      <phone>(+33) 03 26 78 41 54</phone>
      <email>cpluchart@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Hopital Sud Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie TAQUE, MD</last_name>
      <phone>(+33) 02 99 26 58 35</phone>
      <email>sophie.taque@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôp. Charles NICOLLE</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale SCHNEIDER, MD</last_name>
      <phone>(+33) 02 32 88 81 91</phone>
      <email>pascale.schneider@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey DAVID, MD</last_name>
      <phone>(+33) 04 77 82 88 08</phone>
      <email>audrey.david@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine PAILLARD, MD</last_name>
      <phone>(+33) 03.88.12.80.91</phone>
      <email>catherine.paillard@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion GAMBART, MD</last_name>
      <phone>(+33) 05 34 55 84 26</phone>
      <email>gambart.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU TOURS - Hôpital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale BLOUIN, MD</last_name>
      <phone>(+33) 02 47 47 47 51</phone>
      <email>p.blouin@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital d'Enfants</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal CHASTAGNER, MD</last_name>
      <phone>(+33) 03 83 15 47 36</phone>
      <email>p.chastagner@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia PASQUALINI, MD</last_name>
      <phone>(+33) 01 42 11 37 58</phone>
      <email>Claudia.PASQUALINI@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

